ECSP11011285A - Forma cristalina del fosfato de dihidrogeno r)-3-(4-(2-(2-metiltetrazol-5-il)piridin-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona - Google Patents

Forma cristalina del fosfato de dihidrogeno r)-3-(4-(2-(2-metiltetrazol-5-il)piridin-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona

Info

Publication number
ECSP11011285A
ECSP11011285A EC2011011285A ECSP11011285A ECSP11011285A EC SP11011285 A ECSP11011285 A EC SP11011285A EC 2011011285 A EC2011011285 A EC 2011011285A EC SP11011285 A ECSP11011285 A EC SP11011285A EC SP11011285 A ECSP11011285 A EC SP11011285A
Authority
EC
Ecuador
Prior art keywords
crystalline form
fluorophenyl
dihydrogen phosphate
oxazolidin
methylethrazol
Prior art date
Application number
EC2011011285A
Other languages
English (en)
Inventor
Bacher Katharina Reichen
Robert J Duguid
Jacqueline Simson
Douglas Phillipson
Original Assignee
Trius Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trius Therapeutics filed Critical Trius Therapeutics
Publication of ECSP11011285A publication Critical patent/ECSP11011285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una forma cristalina del fosfato de dihidrógeno cristalino (R)-3-(4-(2-(2-metiltetrazol-5-il)piridin-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona, métodos para elaborar la forma cristalina y composiciones farmacéuticas que comprenden la forma cristalina son antibióticos útiles. Además, los derivados de la presente invención pueden ejercer actividad antibacterial potente contra diversos patógenos humanos y animales, incluyendo bacterias grampositivas, tales como Estafilococo, Enterococos y Estreptococos, microorganismos anaeróbicos tales como Bacteroides y Clostridium, y microorganismos resistentes a los ácidos, tales como Micobacteria tuberculosis y Micobacteria aviar. Por consiguiente, las composiciones que comprenden la forma cristalina, pueden usarse en antibióticos.
EC2011011285A 2009-02-03 2011-08-23 Forma cristalina del fosfato de dihidrogeno r)-3-(4-(2-(2-metiltetrazol-5-il)piridin-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona ECSP11011285A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14940209P 2009-02-03 2009-02-03

Publications (1)

Publication Number Publication Date
ECSP11011285A true ECSP11011285A (es) 2011-10-31

Family

ID=42289775

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011285A ECSP11011285A (es) 2009-02-03 2011-08-23 Forma cristalina del fosfato de dihidrogeno r)-3-(4-(2-(2-metiltetrazol-5-il)piridin-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona

Country Status (29)

Country Link
US (6) US8426389B2 (es)
EP (1) EP2393808B1 (es)
JP (1) JP5584705B2 (es)
KR (3) KR101739923B1 (es)
CN (2) CN107082790A (es)
AP (1) AP2987A (es)
AU (1) AU2010210627B2 (es)
BR (1) BRPI1008829A2 (es)
CA (1) CA2751392C (es)
CL (1) CL2011001855A1 (es)
CO (1) CO6620071A2 (es)
CR (1) CR20110464A (es)
CU (1) CU24089B1 (es)
DO (1) DOP2011000251A (es)
EC (1) ECSP11011285A (es)
ES (1) ES2734724T3 (es)
IL (1) IL214401B (es)
MA (1) MA33092B1 (es)
MX (3) MX384300B (es)
MY (1) MY156354A (es)
NZ (3) NZ620458A (es)
PE (1) PE20120585A1 (es)
PH (1) PH12014500092A1 (es)
RU (2) RU2011136537A (es)
SG (2) SG173497A1 (es)
TN (1) TN2011000381A1 (es)
UA (1) UA114068C2 (es)
WO (1) WO2010091131A1 (es)
ZA (2) ZA201106412B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
RU2659792C1 (ru) 2008-10-10 2018-07-04 Мерк Шарп Энд Домэ Корп. Оксазолидиноны и способ их очистки
MX384300B (es) 2009-02-03 2025-03-14 Merck Sharp & Dohme Llc Forma cristalina del fosfato de dihidrogeno r) -3- (4- (2- (2-metiltetrazol-5-il) piridin-5-il) -3-fluorofenil) -5-hidroximetil oxazolidin-2-ona.
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
WO2015054246A1 (en) * 2013-10-07 2015-04-16 Trius Therapeutics, Inc. Methods of treating subjects with renal impairment using tedizolid
CN105229001B (zh) * 2014-04-18 2017-04-26 杭州普晒医药科技有限公司 一种噁唑烷酮类抗生素的晶型及制备方法、组合物和用途
WO2016009401A2 (en) * 2014-07-18 2016-01-21 Dr. Reddy's Laboratories Limited Preparation of tedizolid phosphate
CN104327119A (zh) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 磷酸泰地唑胺的制备方法
WO2016063246A1 (en) * 2014-10-22 2016-04-28 Sun Pharmaceutical Industries Limited Crystalline form r of tedizolid phosphate
WO2016088101A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088102A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088100A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
CZ306245B6 (cs) * 2014-12-11 2016-10-26 Univerzita Karlova v Praze Farmaceutická fakulta v Hradci Králové Substituovaný fenyltetrazol, jeho použití a farmaceutický přípravek ho obsahující
CN104558034A (zh) * 2015-01-21 2015-04-29 齐鲁制药有限公司 磷酸特地唑胺二钠盐的新晶型及其制备方法
CN105837634B (zh) * 2015-01-30 2020-09-04 上海创诺制药有限公司 一种泰地唑胺磷酸酯结晶体及其制备方法
CN104592218B (zh) * 2015-02-13 2015-11-04 江苏欧信医药化工有限公司 一种泰地唑胺的合成方法
CN106146485B (zh) * 2015-04-01 2021-04-30 上海迪赛诺化学制药有限公司 一种制备泰地唑胺的方法及其得到的泰地唑胺结晶体
CN106146558A (zh) * 2015-04-10 2016-11-23 博瑞生物医药（苏州）股份有限公司 新的噁唑烷酮类化合物及其制备方法
CN106317114B (zh) * 2015-07-02 2018-11-20 南京优科制药有限公司 一种磷酸特地唑胺的制备方法
CN105085570B (zh) * 2015-09-12 2017-11-28 山东罗欣药业集团股份有限公司 一种磷酸特地唑胺化合物及其制备方法
CN105287407B (zh) * 2015-11-24 2018-09-21 南京正大天晴制药有限公司 一种注射用磷酸特地唑胺
CN107121503B (zh) * 2017-03-14 2020-04-28 南京优科制药有限公司 一种磷酸特地唑胺及其有关物质的分析方法
CN108948079A (zh) * 2017-05-17 2018-12-07 上海奥博生物医药技术有限公司 一种特地唑胺二铵盐及晶型与其制备方法
EP3723758A4 (en) * 2017-12-13 2021-06-23 Merck Sharp & Dohme Corp. PHARMACEUTICAL COMPOSITIONS OF TEDICOLIDE PHOSPHATE
US12109203B2 (en) 2018-07-25 2024-10-08 Zydus Lifesciences Limited Substituted oxazolidinones for the treatment of mammalian infections
AU2021292747A1 (en) 2020-06-18 2023-02-23 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
CN112957332B (zh) * 2021-02-04 2023-04-25 海南通用康力制药有限公司 注射用磷酸特地唑胺及其质量标准
CN112957333B (zh) * 2021-02-05 2022-11-22 海南通用康力制药有限公司 注射用磷酸特地唑胺及其制备方法
CN113197874B (zh) * 2021-04-28 2023-05-26 北京福元医药股份有限公司 一种磷酸特地唑胺口服固体制剂

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU80081A1 (fr) * 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) * 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4340606A (en) 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2500450A1 (fr) * 1981-02-25 1982-08-27 Delalande Sa Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
US4461773A (en) * 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
CA1320730C (en) 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5144911A (en) * 1990-11-28 1992-09-08 Moore Cheri L Component bed system for a pet
EP0610265B1 (en) * 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
DE69316240T2 (de) * 1992-12-08 1998-05-20 Upjohn Co Durch eine tropon gruppe substituierte phenyloxazolidinone-derivate als antibakterielles mittel
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
NZ274966A (en) 1993-11-22 1998-01-26 Upjohn Co Substituted-hydroxyacetyl piperazine phenyl oxazolidinone derivatives, use in pharmaceutical compositions
GB9702213D0 (en) * 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
NZ522990A (en) * 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
US20020115669A1 (en) * 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
YU52403A (sh) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
DE60212959T2 (de) 2001-04-07 2007-02-15 Astrazeneca Ab Eine sulfonimid-gruppe enthaltende oxazolidinone als antibiotika
US6623140B2 (en) 2001-04-13 2003-09-23 Scott R. Watterson Illumination device having multiple light sources
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2002329393B2 (en) 2001-09-11 2008-06-12 Astrazeneca Ab Oxazolidinone and/or isoxazoline as antibacterial agents
WO2003035648A1 (en) 2001-10-25 2003-05-01 Astrazeneca Ab Aryl substituted oxazolidinones with antibacterial activity
NZ515881A (en) 2001-12-03 2004-09-24 New Zealand Dairy Board Cheese flavour ingredient and method of its production
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
NZ535592A (en) * 2002-02-28 2006-07-28 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
WO2003072576A2 (en) 2002-02-28 2003-09-04 Astrazeneca Ab Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
CA2507628A1 (en) 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
NZ540147A (en) * 2002-11-28 2008-03-28 Astrazeneca Ab Oxazolidinone and/or isoxazoline derivatives as antibacterial agents
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
TW200500360A (en) * 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
GB0306358D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
AU2004256085B2 (en) * 2003-07-02 2007-12-06 Kyorin, Pharmaceutical Co., Ltd. Cyclopropyl Group Substituted Oxazolydinone Antibiotics and Derivatives Thereof
MXPA06000228A (es) * 2003-07-02 2006-06-27 Merck & Co Inc Antibioticos de oxazolidinona sustituidos con un grupo ciclopropilo y derivados de los mismos.
WO2005051933A1 (en) 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
JP2007514782A (ja) * 2003-12-17 2007-06-07 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ハロゲン化ビアリール複素環式化合物ならびにその作製方法および使用方法
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070191336A1 (en) * 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
US20070208062A1 (en) * 2004-05-25 2007-09-06 Astrazeneca Ab 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections
JP2008500318A (ja) * 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 抗菌剤としての３−｛４−（ピリジン−３−イル）フェニル｝−５−（１ｈ−１，２，３−トリアゾール−１−イルメチル）−１，３−オキサゾリジン−２−オン
CA2566963A1 (en) * 2004-05-25 2005-12-08 Astrazeneca Ab 3-[4-{6-substituted alkanoyl pyridin-3-yl}-3-phenyl]-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents
US20080064689A1 (en) * 2004-05-25 2008-03-13 Astrazeneca Ab 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
GB0411596D0 (en) 2004-05-25 2004-06-30 Astrazeneca Ab Chemical process
US20100286211A1 (en) 2004-10-08 2010-11-11 Biswajit Das Oxazolidinone derivatives as antimicrobials
US20090018123A1 (en) * 2005-06-20 2009-01-15 Milind D Sindkhedkar Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation
WO2007138381A2 (en) 2005-10-14 2007-12-06 Targanta Therapeutics Inc. Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
CN101720325B (zh) * 2007-08-06 2013-04-24 上海盟科药业有限公司 用于治疗细菌感染的抗菌邻-氟苯基噁唑烷酮
CN101220001A (zh) * 2008-01-25 2008-07-16 浙江博泰化工有限公司 一种利奈唑酮的合成方法
RU2659792C1 (ru) 2008-10-10 2018-07-04 Мерк Шарп Энд Домэ Корп. Оксазолидиноны и способ их очистки
MX384300B (es) 2009-02-03 2025-03-14 Merck Sharp & Dohme Llc Forma cristalina del fosfato de dihidrogeno r) -3- (4- (2- (2-metiltetrazol-5-il) piridin-5-il) -3-fluorofenil) -5-hidroximetil oxazolidin-2-ona.
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use

Also Published As

Publication number Publication date
KR20170135984A (ko) 2017-12-08
CA2751392A1 (en) 2010-08-12
AP2011005835A0 (en) 2011-08-31
CR20110464A (es) 2016-07-20
EP2393808B1 (en) 2019-05-08
CO6620071A2 (es) 2013-02-15
US20180251482A1 (en) 2018-09-06
KR20170040371A (ko) 2017-04-12
UA114068C2 (xx) 2017-04-25
CU24089B1 (es) 2015-04-29
US20170275315A1 (en) 2017-09-28
TN2011000381A1 (en) 2013-03-27
DOP2011000251A (es) 2011-11-15
RU2011136537A (ru) 2013-03-10
NZ712289A (en) 2017-03-31
SG10201500207QA (en) 2015-03-30
AU2010210627B2 (en) 2016-03-03
IL214401B (en) 2021-03-25
NZ620458A (en) 2015-10-30
US20130310343A1 (en) 2013-11-21
KR101739923B1 (ko) 2017-05-25
CU20110155A7 (es) 2012-02-15
RU2655928C1 (ru) 2018-05-30
US9988406B2 (en) 2018-06-05
US9624250B2 (en) 2017-04-18
MA33092B1 (fr) 2012-03-01
CN102439006A (zh) 2012-05-02
PH12014500092B1 (en) 2014-12-01
NZ594408A (en) 2014-03-28
SG173497A1 (en) 2011-09-29
PH12014500092A1 (en) 2014-12-01
JP5584705B2 (ja) 2014-09-03
US8426389B2 (en) 2013-04-23
US10442829B2 (en) 2019-10-15
MY156354A (en) 2016-02-15
US20160176905A1 (en) 2016-06-23
IL214401A0 (en) 2011-09-27
MX2020011773A (es) 2020-11-24
BRPI1008829A2 (pt) 2016-03-15
CA2751392C (en) 2017-03-28
EP2393808A1 (en) 2011-12-14
ZA201306536B (en) 2014-05-28
KR101918678B1 (ko) 2018-11-14
PE20120585A1 (es) 2012-06-13
US10065947B1 (en) 2018-09-04
ZA201106412B (en) 2013-11-27
US20180244704A1 (en) 2018-08-30
MX2011008093A (es) 2011-11-29
AU2010210627A1 (en) 2011-08-25
ES2734724T3 (es) 2019-12-11
AP2987A (en) 2014-09-30
CL2011001855A1 (es) 2011-11-11
KR20110120311A (ko) 2011-11-03
WO2010091131A1 (en) 2010-08-12
US20100227839A1 (en) 2010-09-09
CN107082790A (zh) 2017-08-22
JP2012516894A (ja) 2012-07-26
MX384300B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
CU20110155A7 (es) Forma cristalina del fosfato de dihidrógeno r)-3-(4-(2-(2-metiltretazol-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona
UY34723A (es) ?compuestos de 7-oxo-1,6-diazabiciclo[3.2.1]oct-3-en-6-ilo sustituidos para usarse como inhibidores de la betalactamasa?.
MX2016011822A (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas.
ECSP13012928A (es) Derivados de fluoro-piridinona útiles como agentes antibacterianos
DOP2017000310A (es) Inhibidores de metalo-beta-lactamasa
EP3912652C0 (en) NANOFIBRILLAR CELLULOSE BIO-INK FOR 3D BIOPRINTING FOR CELL CULTURE, TISSUE ENGINEERING AND REGENERATIVE MEDICINE APPLICATIONS
CL2011000939A1 (es) Compuestos derivados de cefalosporinas sustituidas por un grupo catecol, con actividad antimicrobiana contra bacterias gram negativo que producen betalactamasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades infecciosas.
BR112016007356A2 (pt) compostos herbicidas
UY33316A (es) Compuestos de cefemo que contienen seudocatecol
WO2014022382A3 (en) Antibacterial protein kinase inhibitors
MX339077B (es) Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas.
CO2019001995A2 (es) Inhibidores de beta-lactamasa
TR201000686A1 (tr) Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
BR112017008101A2 (pt) composto, composição farmacêutica, métodos para inibir o dnae bacteriano e para tratar uma infecção, e, uso de um composto.
UY31514A1 (es) Una ciano piperidinil-fenil-oxazolidinona y uso de la misma
MX2015012170A (es) Sales de chorhidrato de un compuesto antibiotico.
CO2018006715A2 (es) Proceso para la inducción de actividad antimicrobiana en bacterias aerobias formadoras de endospora
PH22015000375U3 (en) Process of producing an ointment for treating skin infection caused by staphylococcus aureus bacteria
PH22015000376U1 (en) An ointment for treating skin infection caused by staphylococcus aureus bacteria
RU2014147438A (ru) ШТАММ БАКТЕРИЙ Staphylococcus aureus 113, ИСПОЛЬЗУЕМЫЙ В КАЧЕСТВЕ ТЕСТ-КУЛЬТУРЫ ДЛЯ ОТБОРА АНТИБАКТЕРИАЛЬНЫХ СРЕДСТВ
UY36043A (es) COMPUESTOS ORGÁNICOS DE MONOBACbTAM PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS
PE20140887A1 (es) Tratamiento de infecciones bacterianas
RU2013144008A (ru) ШТАММ ЛАКТОБАКТЕРИЙ Lactobacillus rhamnosus odi 83, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПРЕДПОСЕВНОЙ АКТИВАЦИИ СЕМЯН ТОМАТОВ